ContraVir Pharmaceuticals (NSDQ:CTRV) touted encouraging results today from a preclinical study of its cyclophilin inhibitor, CRV431. In an animal model, the drug reduced the extent of fibrosis by 46% compared to the control. The Edison, N.J.-based biopharma company is developing medicines to treat patients who are infected with the hepatitis B virus. In the treatment […]
